share_log

Vivos Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Thompson Matthew

Vivos Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Thompson Matthew

Vivos Therapeutics | 4：持股變動聲明-董事 Thompson Matthew
美股SEC公告 ·  06/29 08:57
牛牛AI助理已提取核心訊息
In a recent transaction, Matthew Thompson, associated with Vivos Therapeutics, Inc. [VVOS], executed a stock transaction on June 20, 2024. The specific details regarding the nature of the transaction, such as the number of shares involved, the transaction price, and the resulting shareholding, were not disclosed. This event may be of interest to investors who follow Vivos Therapeutics, as insider transactions can provide insights into the company's financial health and future prospects.
In a recent transaction, Matthew Thompson, associated with Vivos Therapeutics, Inc. [VVOS], executed a stock transaction on June 20, 2024. The specific details regarding the nature of the transaction, such as the number of shares involved, the transaction price, and the resulting shareholding, were not disclosed. This event may be of interest to investors who follow Vivos Therapeutics, as insider transactions can provide insights into the company's financial health and future prospects.
近期，與Vivos Therapeutics, Inc. [VVOS]有關的Matthew Thompson在2024年6月20日進行了一筆股票交易。未透露有關交易數量、交易價格及相應的參股金融等具體細節。對於跟蹤Vivos Therapeutics的投資者來說，這一事件可能具有重要意義，因爲內部交易可以提供有關公司財務健康和未來前景的見解。
近期，與Vivos Therapeutics, Inc. [VVOS]有關的Matthew Thompson在2024年6月20日進行了一筆股票交易。未透露有關交易數量、交易價格及相應的參股金融等具體細節。對於跟蹤Vivos Therapeutics的投資者來說，這一事件可能具有重要意義，因爲內部交易可以提供有關公司財務健康和未來前景的見解。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。